DBV Technologies S.A. (DBV.PA)
EUR 1.52
(-4.28%)
EUR 1.52
(-4.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.15 Million EUR | 126.84% |
| 2022 | -15.49 Million USD | -334.71% |
| 2021 | -3.56 Million USD | 76.76% |
| 2020 | -15.34 Million EUR | -463.27% |
| 2019 | -2.72 Million EUR | 35.32% |
| 2018 | -4.21 Million EUR | -43.95% |
| 2017 | -2.92 Million EUR | -116.9% |
| 2016 | -1.34 Million EUR | -1767.39% |
| 2015 | 80.9 Thousand EUR | -10.65% |
| 2014 | 90.54 Thousand EUR | -17.45% |
| 2013 | 109.68 Thousand EUR | -9.26% |
| 2012 | 120.88 Thousand EUR | 52.91% |
| 2011 | 79.05 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.4 Million USD | -84.15% |
| 2024 Q2 | 1.16 Million USD | -17.48% |
| 2023 Q1 | 2.19 Million USD | 268.25% |
| 2023 FY | 4.15 Million EUR | 126.84% |
| 2023 Q4 | 8.87 Million USD | 269.79% |
| 2023 Q3 | 2.4 Million USD | 4.9% |
| 2023 Q2 | 2.28 Million USD | 4.28% |
| 2022 Q3 | 2.07 Million USD | 35.64% |
| 2022 Q4 | -1.3 Million USD | -162.87% |
| 2022 Q1 | 2.54 Million USD | -55.4% |
| 2022 Q2 | 1.52 Million USD | -39.95% |
| 2022 FY | -15.49 Million USD | -334.71% |
| 2021 Q1 | 2.94 Million USD | 342.66% |
| 2021 Q2 | -1.48 Million USD | -150.6% |
| 2021 Q3 | 1.32 Million USD | 188.91% |
| 2021 Q4 | 5.7 Million USD | 331.44% |
| 2021 FY | -3.56 Million USD | 76.76% |
| 2020 Q1 | 4.72 Million USD | 182.22% |
| 2020 Q3 | 4.15 Million USD | 15.18% |
| 2020 FY | -15.34 Million EUR | -463.27% |
| 2020 Q4 | -1.21 Million USD | -129.15% |
| 2020 Q2 | 3.61 Million USD | -23.52% |
| 2019 FY | -2.72 Million EUR | 35.32% |
| 2019 Q4 | 1.67 Million EUR | -33.46% |
| 2019 Q1 | 3.34 Million USD | -6.75% |
| 2019 Q2 | 3.39 Million USD | 1.38% |
| 2019 Q3 | 2.51 Million EUR | -25.98% |
| 2018 FY | -4.21 Million EUR | -43.95% |
| 2018 Q4 | 3.59 Million EUR | 40.28% |
| 2018 Q3 | 2.56 Million EUR | -24.94% |
| 2018 Q2 | 3.41 Million USD | -5.21% |
| 2018 Q1 | 3.59 Million USD | 87.39% |
| 2017 Q2 | 3.65 Million USD | 7.06% |
| 2017 Q3 | 1.89 Million USD | -48.22% |
| 2017 Q4 | 1.92 Million USD | 1.51% |
| 2017 FY | -2.92 Million EUR | -116.9% |
| 2017 Q1 | 3.41 Million USD | 266.67% |
| 2016 Q1 | 2.52 Million USD | 56.55% |
| 2016 FY | -1.34 Million EUR | -1767.39% |
| 2016 Q4 | 930.95 Thousand USD | -6.3% |
| 2016 Q3 | 993.54 Thousand USD | -59.67% |
| 2016 Q2 | 2.46 Million USD | -2.49% |
| 2015 Q1 | 1.48 Million USD | 21.3% |
| 2015 FY | 80.9 Thousand EUR | -10.65% |
| 2015 Q4 | 1.61 Million USD | -2.68% |
| 2015 Q3 | 1.65 Million USD | -7.16% |
| 2015 Q2 | 1.78 Million USD | 20.03% |
| 2014 Q4 | 1.22 Million USD | 0.3% |
| 2014 FY | 90.54 Thousand EUR | -17.45% |
| 2014 Q1 | 1.76 Million USD | 4.73% |
| 2014 Q2 | 1.73 Million USD | -1.21% |
| 2014 Q3 | 1.22 Million USD | -29.65% |
| 2013 Q2 | 834.23 Thousand USD | 1.46% |
| 2013 Q3 | 1.65 Million USD | 97.97% |
| 2013 Q4 | 1.68 Million USD | 1.75% |
| 2013 FY | 109.68 Thousand EUR | -9.26% |
| 2013 Q1 | 822.26 Thousand USD | -12.93% |
| 2012 Q3 | 919.88 Thousand USD | 0.0% |
| 2012 FY | 120.88 Thousand EUR | 52.91% |
| 2012 Q4 | 944.37 Thousand USD | 2.66% |
| 2011 FY | 79.05 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -573.073% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -6.275% |
| Adocia SA | 1.38 Million EUR | -200.332% |
| Aelis Farma SA | 12.35 Million EUR | 66.341% |
| Biophytis S.A. | -803 Thousand EUR | 618.006% |
| Advicenne S.A. | 1.42 Million EUR | -191.696% |
| genOway Société anonyme | 20.1 Million EUR | 79.306% |
| IntegraGen SA | 5.01 Million EUR | 17.111% |
| Medesis Pharma S.A. | -2.66 Million EUR | 256.096% |
| Neovacs S.A. | 29.31 Thousand EUR | -14089.78% |
| NFL Biosciences SA | -56.06 Thousand EUR | 7519.364% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -93.207% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 393.076% |
| Sensorion SA | 3.78 Million EUR | -9.814% |
| Theranexus Société Anonyme | -4.63 Million EUR | 189.672% |
| TME Pharma N.V. | -127 Thousand EUR | 3375.269% |
| Valbiotis SA | 2.66 Million EUR | -55.907% |
| TheraVet SA | -530.79 Thousand EUR | 883.652% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -228.302% |
| Genfit S.A. | 28.22 Million EUR | 85.262% |
| GeNeuro SA | -293.8 Thousand EUR | 1515.79% |
| Innate Pharma S.A. | -4.12 Million EUR | 200.936% |
| Inventiva S.A. | 17.5 Million EUR | 76.231% |
| MaaT Pharma SA | 1.65 Million EUR | -151.335% |
| MedinCell S.A. | 9.28 Million EUR | 55.215% |
| Nanobiotix S.A. | 36.2 Million EUR | 88.512% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -86.78% |
| Poxel S.A. | 1000.00 EUR | -415859.2% |
| GenSight Biologics S.A. | 3 Million EUR | -38.653% |
| Transgene SA | -28.4 Million EUR | 114.644% |
| Valneva SE | 52.83 Million EUR | 92.128% |